mRNA-4157的积极结果，凸显了肿瘤治疗领域的未满足需求，mRNA肿瘤疫苗的市场潜力正被行业广泛看好。麦高证券研报指出，mRNA肿瘤疫苗有潜力成为泛癌种、高可及性、现货化与个性化兼具的新型肿瘤免疫疗法。其可凭借广泛的联用，以辅助疗法切入临床，逐步 ...
斯微生物成立于2016年，中国最早开展mRNA药物研发和mRNA肿瘤精准疫苗人体临床试验的创新型企业之一，公司已掌握了mRNA疫苗的核心技术，拥有LPP纳米递送系统的全球独家权益；拥有自主开发的抗原分析、预测、序列优化平台；拥有年产数亿剂mRNA疫苗 ...
In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...
潇湘晨报 on MSN
mRNA编码药物治疗实体瘤取得进展
【新知】 科技日报讯 （记者张佳星）日前，国际期刊《自然·通讯》发表了剂泰科技自主研发的创新药物MTS-105在肝细胞癌治疗领域的最新研究成果。MTS-105通过mRNA编码生产双特异性抗体，能够发挥衔接器的作用，研究显示，mRNA编码的双特异性抗体T细胞衔接器在肝细胞癌小鼠模型中实现了肿瘤细胞完全清除并诱导长期T细胞免疫记忆，有望成为全球首款mRNA编码 ...
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery ...
A more effective vaccine technology may be on the horizon. In a new study in mice, researchers from the University of Copenhagen demonstrate that a simple addition to mRNA vaccines can significantly ...
Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in mice to a hundred times its stand-alone effectiveness, thus offering ...
Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their ...
mRNA expert Jeff Coller spoke with Live Science about the future of mRNA vaccines in the United States in the aftermath of huge federal funding cuts. When you purchase through links on our site, we ...
Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine—which designs nanotechnology-based ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果